Search

Your search keyword '"Caballero, Teresa"' showing total 651 results
Start Over Author "Caballero, Teresa"
651 results on '"Caballero, Teresa"'

1. Hereditary angioedema in Spain: medical care and patient journey

Author

Caballero, Teresa, Alonso, Carmen, Baeza, María Luisa, Baynova, Krasimira, Cabeza, José, Cortés, Isabel, Escobar Oblitas, Danilo, Guilarte, Mar, Joral, Alejandro, Jurado Palomo, Jesús, Lara Jiménez, María Ángeles, Martínez Virto, Ana, Medrano, Laura, Monte Boquet, Emilio, Navarro, Montserrat, Pérez, Diego, Plá Martí, María José, Smith Foltz, Sara L., Suero, Coral, and Zamora, Carolina

Published
2024
Full Text
View/download PDF

3. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

Author

Reshef, Avner, Buttgereit, Thomas, Betschel, Stephen D., Caballero, Teresa, Farkas, Henriette, Grumach, Anete S., Hide, Michihiro, Jindal, Ankur K., Longhurst, Hilary, Peter, Jonathan, Riedl, Marc A., Zhi, Yuxiang, Aberer, Werner, Abuzakouk, Mohamed, Al Farsi, Tariq, Al Sukaiti, Nashat, Al-Ahmad, Mona, Altrichter, Sabine, Aygören-Pürsün, Emel, Baeza, Maria Luisa, Bara, Noemi Anna, Bauer, Andrea, Bernstein, Jonathan A., Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Bygum, Anette, Calderon, Oscar, de Albuquerque Campos, Regis, Campos Romero, Freya Helena, Cancian, Mauro, Chong-Neto, Herberto Jose, Christoff, George, Cimbollek, Stefan, Cohn, Danny M., Craig, Timothy, Danilycheva, Inna, Darlenski, Razvigor, Du-Thanh, Aurélie, Ensina, Luis Felipe, Fomina, Daria, Fonacier, Luz, Fukunaga, Atsushi, Gelincik, Asli, Giavina-Bianchi, Pedro, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Guidos-Fogelbach, Guillermo, Guilarte, Mar, Kasperska-Zajac, Alicja, Katelaris, Constance H., Kinaciyan, Tamar, Kolkhir, Pavel, Kulthanan, Kanokvalai, Kurowski, Marcin, Latysheva, Elena, Lauerma, Antti, Launay, David, Lleonart, Ramon, Lumry, William, Malbran, Alejandro, Ali, Ramzy Mohammed, Nasr, Iman, Nieto-Martinez, Sandra, Parisi, Claudio, Pawankar, Ruby, Piñero-Saavedra, Macarena, Popov, Todor A., Porebski, Grzegorz, Prieto Garcia, Alicia, Pyatilova, Polina, Rudenko, Michael, Sekerel, Bulent Enis, Serpa, Faradiba Sarquis, Sheikh, Farrukh, Siebenhaar, Frank, Soria, Angèle, Staevska, Maria, Staubach, Petra, Stobiecki, Marcin, Thomsen, Simon Francis, Triggiani, Massimo, Valerieva, Anna, Valle, Solange, Van Dinh, Nguyen, Vera Ayala, Carolina Elisa, Zalewska-Janowska, Anna, Zanichelli, Andrea, Magerl, Markus, and Maurer, Marcus

Published
2024
Full Text
View/download PDF

4. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

Author

Maurer, Marcus, Magerl, Markus, Betschel, Stephen, Aberer, Werner, Ansotegui, Ignacio J, Aygören-Pürsün, Emel, Banerji, Aleena, Bara, Noémi-Anna, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Busse, Paula J, Bygum, Anette, Caballero, Teresa, Cancian, Mauro, Castaldo, Anthony J, Cohn, Danny M, Csuka, Dorottya, Farkas, Henriette, Gompels, Mark, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Kang, Hye-Ryun, Kaplan, Allen P, Katelaris, Constance H, Kiani-Alikhan, Sorena, Lei, Wei-Te, Lockey, Richard F, Longhurst, Hilary, Lumry, William, MacGinnitie, Andrew, Malbran, Alejandro, Saguer, Inmaculada Martinez, Campos, Juan José Matta, Nast, Alexander, Nguyen, Dinh, Nieto-Martinez, Sandra A, Pawankar, Ruby, Peter, Jonathan, Porebski, Grzegorz, Prior, Nieves, Reshef, Avner, Riedl, Marc, Ritchie, Bruce, Sheikh, Farrukh Rafique, Smith, William B, Spaeth, Peter J, Stobiecki, Marcin, Toubi, Elias, Varga, Lilian Agnes, Weller, Karsten, Zanichelli, Andrea, Zhi, Yuxiang, Zuraw, Bruce, and Craig, Timothy

Subjects
Prevention, Clinical Research, C1-inhibitor, DELPHI, GRADE therapy, Hereditary angioedema, diagnosis, disease control, guideline, management, prophylaxis, quality of life, recommendations, self-administration, Clinical Sciences
Abstract

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2), by providing guidance on common and important clinical issues, such as: 1) How should HAE be diagnosed? 2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? 3) What are the goals of treatment? 4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast feeding women? 5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

Published
2022

9. Consensus on treatment goals in hereditary angioedema: A global Delphi initiative

Author

Maurer, Marcus, Aygören-Pürsün, Emel, Banerji, Aleena, Bernstein, Jonathan A., Balle Boysen, Henrik, Busse, Paula J., Bygum, Anette, Caballero, Teresa, Castaldo, Anthony J., Christiansen, Sandra C., Craig, Timothy, Farkas, Henriette, Grumach, Anete S., Hide, Michihiro, Katelaris, Constance H., Li, H. Henry, Longhurst, Hilary, Lumry, William R., Magerl, Markus, Martinez-Saguer, Inmaculada, Riedl, Marc A., Zhi, Yuxiang, and Zuraw, Bruce

Published
2021
Full Text
View/download PDF

12. International Consensus on the Use of Genetics in the Management of Hereditary Angioedema

Author

Andrejevic, Sladjana, Aygören-Pürsün, Emel, Bara, Noemi-Anna, Bernstein, Jonathan, Bork, Konrad, Bouillet, Laurence, Bova, Maria, Boysen, Henrik Halle, Bygum, Anette, Caballero, Teresa, Castaldo, Anthony, Christiansen, Sandra, Cicardi, Marco, Fabiani, Jose, Katelaris, Connie, Dewald, Georg, Gökmen, Nihal M., Gonzalez-Quevedo, Maria Teresa, Gooi, Jimmy, Grivcheva-Panovska, Vesna, Grumach, Anete, Hakl, Roman, Hardy, Gaelle, Jesenak, Milos, Kaplan, Allen, Kirschfink, Michael, Köhalmi, Kinga Viktoria, Leibovich, Iris, Longhurst, Hilary J., Lumry, William, Magerl, Markus, Saguer, Inmaculada Martinez, Nagy, Imola Beatrix, Nieto, Sandra, Nordenfelt, Patrik, Porębski, Grzegorz, Psarros, Fotis, Reshef, Avner, Riedl, Marc A., Sheikh, Farrukh, Peter, Spath, Speletas, Matthaios, Staevska, Maria, Stobiecki, Marcin, Triggiani, Massimo, Veszeli, Nora, Waserman, Susan, Weber, Christina, Wuillemin, Walter, Zuraw, Bruce, Germenis, Anastasios E., Margaglione, Maurizio, Pesquero, João Bosco, Farkas, Henriette, Cichon, Sven, Csuka, Dorottya, Lera, Alberto López, Rijavec, Matija, Jolles, Stephen, Szilagyi, Agnes, Trascasa, Margarita López, Veronez, Camila Lopes, Drouet, Christian, and Zamanakou, Maria

Published
2020
Full Text
View/download PDF

14. Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies.

Author

Bonner, Nicola, Abetz-Webb, Linda, Renault, Lydie, Caballero, Teresa, Longhurst, Hilary, Maurer, Marcus, Christiansen, Sandra, Zuraw, Bruce, and Icatibant Outcome Survey (IOS) International Executive Committee and the Hereditary Angioedema Association (HAEA) Medical Advisory Board

Subjects
Icatibant Outcome Survey (IOS) International Executive Committee and the Hereditary Angioedema Association (HAEA) Medical Advisory Board, Humans, Severity of Illness Index, Reproducibility of Results, Psychometrics, Quality of Life, Adult, Aged, Middle Aged, United States, Argentina, Brazil, Germany, Female, Male, Young Adult, Angioedemas, Hereditary, Patient Outcome Assessment, Surveys and Questionnaires, United Kingdom, Clinical Research, 7.1 Individual care needs, Management of diseases and conditions, Hereditary angioedema, Patient reported outcome, Questionnaire, Qualitative, Patient, Concept elicitation, Cognitive debriefing, Content validity, Public Health and Health Services, Health Policy & Services
Abstract

BackgroundHereditary Angioedema (HAE), a rare genetic disease, manifests as intermittent, painful attacks of angioedema. Attacks vary in frequency and severity and include skin, abdominal and life-threatening laryngeal swellings. This study aimed to develop a patient reported outcome (PRO) tool for the assessment of HAE attacks, including their management and impact on patients' lives, for use in clinical studies, or by physicians in general practice.MethodsThe results of open-ended face to face concept elicitation interviews with HAE patients in Argentina (n = 10) and the US (n = 33) were used to develop the first draft questionnaire of the HAE patient reported outcomes questionnaire (HAE PRO). Subsequently, in-depth cognitive debriefing interviews were performed with HAE patients in the UK (n = 10), Brazil (n = 10), Germany (n = 11) and France (n = 12). Following input from eight multinational clinical experts further cognitive interviews were conducted in the US (n = 12) and Germany (n = 12). Patients who experienced abdominal, cutaneous or laryngeal attacks of varying severity levels were included in all rounds of interviews. Across the rounds of interviews patients discussed their HAE attack symptoms, impacts and treatments. Cognitive debriefing interviews explored patient understanding and relevance of questionnaire items. All interviews were conducted face to face following a pre-defined semi-structured interview guide in the patient's native language.ResultsPatients reported a variety of HAE symptoms, attack triggers, warning signs, attack impacts and treatment options which were used to develop the HAE PRO. The HAE PRO was revised and refined following input from patients and clinical experts. The final 18-item HAE PRO provides an assessment of the HAE attack experience including symptoms, impacts, treatment requirements, healthcare resource use and loss of productivity caused by HAE attacks.ConclusionsPatient and expert input has contributed to the development of a content valid questionnaire that assesses concepts important to HAE patients globally. HAE patients across cultures consider the HAE PRO a relevant and appropriate assessment of HAE attacks and treatment.

Published
2015

15. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks

Author

Craig, Timothy, Zuraw, Bruce, Longhurst, Hilary, Cicardi, Marco, Bork, Konrad, Grattan, Clive, Katelaris, Constance, Sussman, Gordon, Keith, Paul K., Yang, William, Hébert, Jacques, Hanzlikova, Jana, Staubach-Renz, Petra, Martinez-Saguer, Inmaculada, Magerl, Markus, Aygören-Pürsün, Emel, Farkas, Henriette, Reshef, Avner, Kivity, Shmuel, Neri, Sergio, Crisan, Ioana, Caballero, Teresa, Baeza, Maria L., Hernandez, Maria Dolores, Li, Henry, Lumry, William, Bernstein, Jonathan A., Hussain, Iftikar, Anderson, John, Schwartz, Lawrence B., Jacobs, Joshua, Manning, Michael, Levy, Donald, Riedl, Marc, Christiansen, Sandra, Feuersenger, Henrike, Pragst, Ingo, Mycroft, Sarah, Pawaskar, Dipti, and Jacobs, Iris

Published
2019
Full Text
View/download PDF

17. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial

Author

Kiani-Alikhan, Sorena, primary, Gower, Richard, additional, Craig, Timothy, additional, Wedner, H. James, additional, Kinaciyan, Tamar, additional, Aygören-Pürsün, Emel, additional, Banerji, Aleena, additional, Bernstein, Jonathan A., additional, Anderson, John, additional, Collis, Phil, additional, Johnston, Douglas T., additional, Desai, Bhavisha, additional, Tomita, Dianne, additional, Gagnon, Rémi, additional, Tachdjian, Raffi, additional, Soteres, Daniel F., additional, Farkas, Henriette, additional, Caballero, Teresa, additional, McNeil, Donald, additional, Jacobs, Joshua, additional, and Lumry, William R., additional

Published
2024
Full Text
View/download PDF

18. Understanding The Reasons Not To Treat All HAE Attacks And Patient Satisfaction For On-Demand Treatment (ODT). Results From The HAE Wave II Disease Specific Program™ (DSP™) 2023

Author

Mendivil, Joan, primary, Anderson, John, additional, Bouillet, Laurence, additional, Busse, Paula, additional, Caballero, Teresa, additional, Lumry, William, additional, Magerl, Markus, additional, Riedl, Marc, additional, Yong, Patrick, additional, Zanichelli, Andrea, additional, and Earl, Lucy, additional

Published
2024
Full Text
View/download PDF

23. Advent of oral medications for the treatment of hereditary angioedema.

Author

Valerieva, Anna, Caballero, Teresa, Magerl, Markus, Frade, Joao P., Audhya, Paul K., and Craig, Timothy

Subjects
*CLINICAL trials, *BRADYKININ receptors, *CORPORATE websites, *INTRAVENOUS therapy
Abstract

Background: Hereditary angioedema (HAE) is a rare genetic disorder characterized by unpredictable, debilitating episodes of submucosal and/or subcutaneous tissue swelling, which may be life‐threatening depending on anatomic location. The two primary management strategies for HAE are ready access to effective on‐demand treatment in all patients and the prevention of attacks (short‐term prophylaxis [STP] and long‐term prophylaxis [LTP]) in appropriate patients. All approved on‐demand and most LTP medications require subcutaneous or intravenous administration. Injection‐related challenges include trypanophobia (fear of needles), difficulty with self‐administration, injection‐site reactions (e.g., pain, erythema, bleeding, bruising), and anxiety—all contributing to poor compliance and administration delays. Oral HAE treatments may improve outcomes by reducing treatment barriers. Aim: To review oral therapies, approved or in development, for on‐demand treatment and/or prevention of HAE attacks. Materials and Methods: To provide a comprehensive review, data was obtained from publicly available resources through a targeted PubMed literature review and supplemented by information provided on company websites (search cutoff of May 31, 2024). Results: Berotralstat, an oral plasma kallikrein (PKa) inhibitor, is approved for LTP. Sebetralstat, another PKa inhibitor, is the investigational first oral on‐demand HAE treatment to complete a phase 3 trial. Deucrictibant, an oral bradykinin B2 receptor antagonist, has completed phase 2 trials for on‐demand therapy and LTP. Several other oral PKa inhibitors (ATN249, VE‐4666, and VE‐4062) are in early development for LTP. Conclusion: Substantial advances have been made in the development of oral treatments for HAE. These treatments have the potential to improve and optimize clinical outcomes, satisfaction, and quality of life among patients with HAE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema

Author

Lumry, William R., Craig, Timothy, Zuraw, Bruce, Longhurst, Hilary, Baker, James, Li, H. Henry, Bernstein, Jonathan A., Anderson, John, Riedl, Marc A., Manning, Michael E., Keith, Paul K., Levy, Donald S., Caballero, Teresa, Banerji, Aleena, Gower, Richard G., Farkas, Henriette, Lawo, John-Philip, Pragst, Ingo, Machnig, Thomas, and Watson, Douglas J.

Published
2018
Full Text
View/download PDF

26. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

Author

Bowen, Tom, Cicardi, Marco, Farkas, Henriette, Bork, Konrad, Longhurst, Hilary J, Zuraw, Bruce, Aygoeren-Pürsün, Emel, Craig, Timothy, Binkley, Karen, Hebert, Jacques, Ritchie, Bruce, Bouillet, Laurence, Betschel, Stephen, Cogar, Della, Dean, John, Devaraj, Ramachand, Hamed, Azza, Kamra, Palinder, Keith, Paul K, Lacuesta, Gina, Leith, Eric, Lyons, Harriet, Mace, Sean, Mako, Barbara, Neurath, Doris, Poon, Man-Chiu, Rivard, Georges-Etienne, Schellenberg, Robert, Rowan, Dereth, Rowe, Anne, Stark, Donald, Sur, Smeeksha, Tsai, Ellie, Warrington, Richard, Waserman, Susan, Ameratunga, Rohan, Bernstein, Jonathan, Björkander, Janne, Brosz, Kristylea, Brosz, John, Bygum, Anette, Caballero, Teresa, Frank, Mike, Fust, George, Harmat, George, Kanani, Amin, Kreuz, Wolfhart, Levi, Marcel, Li, Henry, Martinez-Saguer, Inmaculada, Moldovan, Dumitru, Nagy, Istvan, Nielsen, Erik W, Nordenfelt, Patrik, Reshef, Avner, Rusicke, Eva, Smith-Foltz, Sarah, Späth, Peter, Varga, Lilian, and Xiang, Zhi

Abstract

Abstract Background We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) and updated this as Hereditary angioedema: a current state-of-the-art review: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Objective To update the International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema (circa 2010). Methods The Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'angioédème héréditaire (RCAH) http://www.haecanada.com and cosponsors University of Calgary and the Canadian Society of Allergy and Clinical Immunology (with an unrestricted educational grant from CSL Behring) held our third Conference May 15th to 16th, 2010 in Toronto Canada to update our consensus approach. The Consensus document was reviewed at the meeting and then circulated for review. Results This manuscript is the 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema that resulted from that conference. Conclusions Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches including quality of life and cost benefit analyses, followed by large head-to-head clinical trials and then evidence-based guidelines and standards for HAE disease management.

Published
2010

27. HAE international home therapy consensus document

Author

Longhurst, Hilary J, Farkas, Henriette, Craig, Timothy, Aygören-Pürsün, Emel, Bethune, Claire, Bjorkander, Janne, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik, Bygum, Anette, Caballero, Teresa, Cicardi, Marco, Dempster, John, Gompels, Mark, Gooi, Jimmy, Grigoriadou, Sofia, Huffer, Ursula, Kreuz, Wolfhart, Levi, Marcel M, Long, Janet, Martinez-Saguer, Inmaculada, Raguet, Michel, Reshef, Avner, Bowen, Tom, and Zuraw, Bruce

Abstract

Abstract Hereditary angioedema (C1 inhibitor deficiency, HAE) is associated with intermittent swellings which are disabling and may be fatal. Effective treatments are available and these are most useful when given early in the course of the swelling. The requirement to attend a medical facility for parenteral treatment results in delays. Home therapy offers the possibility of earlier treatment and better symptom control, enabling patients to live more healthy, productive lives. This paper examines the evidence for patient-controlled home treatment of acute attacks ('self or assisted administration') and suggests a framework for patients and physicians interested in participating in home or self-administration programmes. It represents the opinion of the authors who have a wide range of expert experience in the management of HAE.

Published
2010

30. Correction to: The International/Canadian Hereditary Angioedema Guideline

Author

Betschel, Stephen, Badiou, Jacquie, Binkley, Karen, Borici-Mazi, Rozita, Hébert, Jacques, Kanani, Amin, Keith, Paul, Lacuesta, Gina, Waserman, Susan, Yang, Bill, Aygören-Pürsün, Emel, Bernstein, Jonathan, Bork, Konrad, Caballero, Teresa, Cicardi, Marco, Craig, Timothy, Farkas, Henriette, Grumach, Anete, Katelaris, Connie, Longhurst, Hilary, Riedl, Marc, Zuraw, Bruce, Berger, Magdelena, Boursiquot, Jean-Nicolas, Boysen, Henrik, Castaldo, Anthony, Chapdelaine, Hugo, Connors, Lori, Fu, Lisa, Goodyear, Dawn, Haynes, Alison, Kamra, Palinder, Kim, Harold, Lang-Robertson, Kelly, Leith, Eric, McCusker, Christine, Moote, Bill, O’Keefe, Andrew, Othman, Ibraheem, Poon, Man-Chiu, Ritchie, Bruce, St-Pierre, Charles, Stark, Donald, and Tsai, Ellie

Published
2020
Full Text
View/download PDF

31. LA REUTILIZACIÓN DEL AGUA Y LA ECONOMÍA CIRCULAR.

Author

Navarro Caballero, Teresa M.

Subjects
WATER reuse, WATER distribution, RAINFALL, WATER laws, WATER supply
Abstract

Copyright of Revista Catalana de Dret Públic is the property of Revista Catalana de Dret Public and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

32. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting

Author

Aberer, W., Grumach, A., Bygum, A., Blanchard Delaunay, C., Bouillet, L., Coppere, B., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Arnolds, J., Aygören-Pürsün, E., Baş, M., Bauer, A., Bork, K., Martinez, I., Maurer, M., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Cicardi, M., Manconi, P., Marone, G., Montinaro, V., Baeza, M.L., Caballero, T., Cabañas, R., Guilarte, M., Hernandez de Rojas, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Sáenz de San Pedro, B., Bjorkander, J., Helbert, M., Longhurst, H.J., Zanichelli, Andrea, Longhurst, Hilary J., Maurer, Marcus, Bouillet, Laurence, Aberer, Werner, Fabien, Vincent, Andresen, Irmgard, and Caballero, Teresa

Published
2016
Full Text
View/download PDF

33. Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL

Author

Prior, Nieves, Remor, Eduardo, Pérez-Fernández, Elia, Caminoa, Magdalena, Gómez-Traseira, Carmen, Gayá, Francisco, Aabom, Anne, Aberer, Werner, Betschel, Stephen, Boccon-Gibod, Isabelle, Bouillet, Laurence, Bygum, Anette, Csuka, Dorottya, Farkas, Henriette, Gomide, Maria, Grumach, Anete, Leibovich, Iris, Malbran, Alejandro, Moldovan, Dumitru, Mihaly, Eniko, Obtulowicz, Krystyna, Perpén, Cecilia, Peveling-Oberhag, Adriane, Porebski, Grzegorz, Chavannes, Celine Rayonne, Reshef, Avner, Staubach, Petra, Wiednig, Michaela, and Caballero, Teresa

Published
2016
Full Text
View/download PDF

34. The International/Canadian Hereditary Angioedema Guideline

Author

Betschel, Stephen, Badiou, Jacquie, Binkley, Karen, Borici-Mazi, Rozita, Hébert, Jacques, Kanani, Amin, Keith, Paul, Lacuesta, Gina, Waserman, Susan, Yang, Bill, Aygören-Pürsün, Emel, Bernstein, Jonathan, Bork, Konrad, Caballero, Teresa, Cicardi, Marco, Craig, Timothy, Farkas, Henriette, Grumach, Anete, Katelaris, Connie, Longhurst, Hilary, Riedl, Marc, Zuraw, Bruce, Berger, Magdelena, Boursiquot, Jean-Nicolas, Boysen, Henrik, Castaldo, Anthony, Chapdelaine, Hugo, Connors, Lori, Fu, Lisa, Goodyear, Dawn, Haynes, Alison, Kamra, Palinder, Kim, Harold, Lang-Robertson, Kelly, Leith, Eric, McCusker, Christine, Moote, Bill, O’Keefe, Andrew, Othman, Ibraheem, Poon, Man-Chiu, Ritchie, Bruce, St-Pierre, Charles, Stark, Donald, and Tsai, Ellie

Published
2019
Full Text
View/download PDF

38. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema

Author

Maurer, Marcus, Aberer, Werner, Caballero, Teresa, Bouillet, Laurence, Grumach, Anete S, Botha, Jaco, Andresen, Irmgard, Longhurst, Hilary J, IOS Study Group, Maurer, Marcus [0000-0002-4121-481X], Caballero, Teresa [0000-0003-3005-9858], Bouillet, Laurence [0000-0001-8245-4767], Grumach, Anete S [0000-0002-9803-0309], Botha, Jaco [0000-0001-8974-2438], and Apollo - University of Cambridge Repository

Subjects
Treatment Outcome, Adolescent, icatibant, Bradykinin B2 Receptor Antagonists, Angioedemas, Hereditary, acute treatment, Humans, observational, registry, Bradykinin, Child, hereditary angioedema
Abstract

In patients with hereditary angioedema (HAE), bradykinin causes swelling episodes by activating bradykinin B2 receptors. Icatibant, a selective bradykinin B2 receptor antagonist, is approved for on-demand treatment of HAE attacks. The Icatibant Outcome Survey (IOS; NCT01034969) is an ongoing observational registry initiated in 2009 to monitor the effectiveness/safety of icatibant in routine clinical practice. As of March 2019, 549 patients with HAE type 1 or 2 from the IOS registry had been treated of 5995 total attacks. This article reviews data published from IOS over time which have demonstrated that the effectiveness of icatibant in a real-world setting is comparable to efficacy in clinical trials; one dose is effective for the majority of attacks; early treatment (facilitated by self-administration) leads to faster resolution and shorter attack duration; effectiveness/safety of icatibant has been shown across a broad range of patient subgroups, including children/adolescents and patients with HAE with normal C1 inhibitor levels; and tolerability has been demonstrated in patients aged ≥65 years. Additionally, this review highlights how IOS data have provided valuable insights into patients' diagnostic journeys and treatment behaviours across individual countries. Such findings have helped to inform clinical strategies and guidelines to optimise HAE management and limit disease burden. This research was sponsored by Takeda Development Center Americas, Inc. Takeda Development Center Americas, Inc., provided funding to Excel Medical Affairs for support in writing and editing this manuscript.

Published
2022

42. Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?

Author

Narváez-Fernández, Emilio José, Entrala, Ana, Nin-Valencia, Ana, Mir-Ihara, Patricia, Losantos-García, Itsaso, Domínguez-Ortega, Javier, González-Fernández, María Ángeles, Quirce, Santiago, Hernández-Cano, Natalia, Cabañas, Rosario, and Caballero, Teresa

Subjects
OLDER patients, OMALIZUMAB, MANN Whitney U Test, URTICARIA, OLDER people
Abstract

Background: Biologics have revolutionized the treatment of many diseases. In this regard, omalizumab (OMA), an anti-IgE monoclonal antibody, is the recommended therapeutic option for patients with chronic spontaneous urticaria (CSU) refractory to second-generation H1-antihistamines. Several studies confirm the efficacy and safety of the drug. However, the literature focusing on the elderly population is scarce, as this age group is often excluded from clinical trials. Therefore, the pharmacological treatment of CSU in elderly patients is a challenge that is increased by their comorbidities and consequent polypharmacy. Objectives: We describe the real-life safety profile of OMA in elderly patients (≥70 years) with CSU and chronic inducible urticaria (CIndU). We aimed to provide data for daily clinical practice in this vulnerable patient group. Method: A retrospective review was performed of the records of patients with CSU/CIndU from May 2003 to December 2019 in the Hospital Universitario La Paz. We describe qualitative and quantitative data according to measures of central tendency. Comparisons between qualitative and quantitative data were performed with the Mann-Whitney U test and the Fisher's test for qualitative variables. A p value <0.05 was considered statistically significant. Results and Conclusions: Eighty-nine patients were included, divided into two groups (<70 vs. ≥70 years). The overall rate of adverse events (AEs) was 48%, mainly mild. No association between age and AE was found (p = 0.789). No serious AE such as anaphylaxis was detected. CSU predominated in both groups. CIndU was less prevalent in the elderly (p = 0.017). There was no association between age and the other variables. Although the frequency of neoplasms was slightly higher in the elderly with OMA, we found no difference compared to the incidence of neoplasms in the general population. Therefore, our data suggest that OMA may be a safe treatment in elderly people with CSU/CIndU for prolonged periods of treatment, although further studies with larger samples are needed to corroborate our observations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials

Author

Rodriguez Arbolí, Eduardo, primary, Lee, Catherine J., additional, Caballero, Teresa, additional, Garcia-Calderon, Clara, additional, Martinez, Carmen, additional, Bermudez, Maria Aranzazu, additional, López Corral, Lucía, additional, Triguero, Ana, additional, Onstad, Lynn E., additional, Sarantopoulos, Stefanie, additional, Lee, Stephanie J., additional, and Perez-Simon, Jose A., additional

Published
2022
Full Text
View/download PDF

47. Detection, Monitoring and Cell Kinetics of Circulating CAR-T Cells in B-Cell Malignancies

Author

Sierro, Belén, primary, Garcia-Calderon, Clara Beatriz, additional, Sanoja-Flores, Luzalba, additional, Ruiz-Maldonado, Victoria, additional, Delgado Serrano, Javier, additional, Molinos-Quintana, Agueda, additional, Reguera, Juan Luis, additional, Guijarro-Albaladejo, Beatriz, additional, Reinoso-Segura, Marta, additional, Garcia-Guerrero, Estefania, additional, Perez-Simon, Jose A., additional, and Caballero, Teresa, additional

Published
2022
Full Text
View/download PDF

48. SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Author

Falantes, Jose F., primary, Márquez-Malaver, Francisco J., additional, Carrillo-Cruz, Estrella, additional, Morales-Camacho, Rosario M, additional, Prats-Martín, Concepción, additional, Caballero, Teresa, additional, Rodriguez Arbolí, Eduardo, additional, Espigado, Ildefonso, additional, and Perez-Simon, Jose A., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results